Pembrolizumab

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney cancer, according to results of a phase 1 trial.

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced gastroesophageal adenocarcinoma, according to the agents’ manufacturers.

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune response, according to updated results of a phase 1 trial.

Gastric Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors for the disease.

Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.

BOSTON — Physicians suspect the solvent used in the administration of pembrolizumab may have triggered recurrent angioedema for a patient with squamous cell carcinoma, according to a poster presented at the CHEST Annual Meeting.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, talked about survival data from KEYNOTE-522 that have been awaited with “a lot of anticipation.”

Nancy Lin, MD, from the department of medical oncology at Dana-Farber Cancer Institute, discussed exciting OS data from the KEYNOTE-522 study presented at ESMO Congress.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 World Conference on Lung Cancer, as well as Healio’s top headlines from the meeting.

A randomized phase 3 trial designed to compare an investigational combination with standard care for certain patients with advanced colorectal cancer failed to meet its primary endpoint of OS.